| 產品名稱 |
9F12 |
| 商品貨號 |
B163857 |
| Organism |
human (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Human peripheral blood mononuclear cells (enriched for B cells) were fused with P3X63Ag8.653 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against tetanus toxin |
| Cellular Products |
immunoglobulin; monoclonal antibody; against tetanus toxin |
| Comments |
Human peripheral blood mononuclear cells (enriched for B cells) were fused with P3X63Ag8.653 myeloma cells. |
| Complete Growth Medium |
RPMI 1640 medium with 2 mM L-glutamine, 1 mM sodium pyruvate, 5 mcg/ml insulin and 5 mcg/ml transferrin, 85%; fetal bovine serum, 15%
|
| Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
| Culture Conditions |
Temperature: 37.0°C |
| Isotype |
IgG1 |
| Name of Depositor |
University of Rochester Medical Center |
| Deposited As |
human (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Gigliotti F, Insel RA. Protective human hybridoma antibody to tetanus toxin. J. Clin. Invest. 70: 1306-1309, 1982. PubMed: 7174795
Insel RA. Human monoclonal antibodies against bacterial toxins. US Patent 4,689,299 dated Aug 25 1987
Gigliotti F, et al. Reproducible production of protective human monoclonal antibodies by fusion of peripheral blood lymphocytes with a mouse myeloma cell line. J. Infect. Dis. 149: 43-47, 1984. PubMed: 6607295
|
